Methods for treating cognitive deficits in schizophrenia

References

• Bleuler E. (Ed.). Dementia Praecox; or the Group of Schizophrenias. New York: International Universities Press, NY, USA (1911).
   Google Scholar
• Kraepelin E. (Ed.). Dementia Praecox and Paraphrenia. E & S Livingstone, Edinburgh, UK (1919).
   Google Scholar
• Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psych.151, 1409–1416 (1994).
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psych.153, 321–330 (1996).
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Braff DL et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff?” Schizophr. Bull.26, 119–136 (2000).
   PubMed Web of Science ®Google Scholar
• Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res.72, 41–51 (2004).
   PubMed Web of Science ®Google Scholar
• Bowie CR, Reichenberg A, Rieckmann N et al. Stability and functional correlates of memory-based classification in older schizophrenia patients. Am. J. Geriatr. Psych.12(4), 376–386 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman JI, Harvey PD, Coleman T et al. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer’s disease and normal aging. Am. J. Psych.158, 1441–1448 (2001).
   PubMed Web of Science ®Google Scholar
• Oner O, Munir K. Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children. Schizophr. Res.76(2–3), 293–299 (2005).
   PubMed Web of Science ®Google Scholar
• Asarnow RF, Nuechterlein KH, Subotnik KL et al. Neurocognitive impairments in nonpsychotic parents of children with schizophrenia and attention-deficit/hyperactivity disorder: the University of California, Los Angeles Family Study. Arch. Gen. Psych. 59(11), 1053–1060 (2002).
   PubMed Web of Science ®Google Scholar
• Cornblatt BA, Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J. Abnorm. Psychol.94(4), 470–486 (1985).
   PubMed Web of Science ®Google Scholar
• Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am. J. Psych. 156(9), 1328–1335 (1999).
   PubMed Web of Science ®Google Scholar
• Heaton RK, Gladjso JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psych.58(1), 24–32 (2001).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Green MF, Bowie C et al. The dimensions of clinical change in schizophrenia: evidence for independence from cognitive improvement. Neuropsychopharmacol.187(3), 356–363 (2006).
   Google Scholar
• Addington J, Addington G, Gasbarre L. Distractability and symptoms in schizophrenia. J. Psychiatry Neurosci.22(3), 180–184 (1997).
   PubMed Web of Science ®Google Scholar
• Seidman LJ, Buka SL, Goldstein JM, Tsuang MT. Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. J. Clin. Exp. Neuropsychol.28, 225–242 (2006).
   Google Scholar
• Bilder RM, Reiter G, Bates J et al. Cognitive development in schizophrenia: follow-back from the first episode. J. Clin. Exp. Neuropsychol.28, 270–282 (2006).
   PubMed Web of Science ®Google Scholar
• Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol. Psych.55, 1013–1022 (2004).
   PubMed Web of Science ®Google Scholar
• Serper MR, Bergman RL, Harvey PD. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res.32, 281–288 (1990).
   PubMed Web of Science ®Google Scholar
• Earle-Boyer EA, Serper MR, Davidson M, Harvey PD. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res.37, 47–56 (1991).
   PubMed Web of Science ®Google Scholar
• Serper MR, Davidson M, Harvey PD. Attentional predictors of clinical change during neuroleptic treatment in schizophrenia. Schizophr. Res.13, 65–71 (1994).
   PubMed Web of Science ®Google Scholar
• Sweeney JA, Keilp JG, Haas GL, Hill J, Seiden PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res.37, 297–308 (1991).
   PubMed Web of Science ®Google Scholar
• Sweeney JA, Haas GL, Keilp JG, Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year follow up study. Psychiatry Res.38, 63–76 (1991).
   PubMed Web of Science ®Google Scholar
• Davidson M, Harvey PD, Powchik P et al. Severity of symptoms in chronically ill institutionalized geriatric schizophrenic patients. Am. J. Psych.152(2), 197–207 (1995).
   PubMed Web of Science ®Google Scholar
• Strauss ME, Reynolds KS, Jayaram G et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr. Res.3, 127–129 (1990).
   PubMed Web of Science ®Google Scholar
• Brebion G, Bressan RA, Amador X, Malaspina D, Gorman JM. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol. Med. 34, 369–374 (2004).
   PubMed Web of Science ®Google Scholar
• McGurk SR, Green MF, Wirshing WC et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr. Res.68, 225–233 (2004).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs. Compr. Psych.30, 135–138, (1989).
   PubMed Web of Science ®Google Scholar
• Drimer T, Shahal B, Barak Y. Effects of discontinuation of long-term anticholinergic treatment in elderly schizophrenia patients. Int. Clin. Psychopharmacol.19, 27–29 (2004).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Keefe RSE. Interpreting studies of cognitive change in schizophrenia with novel antipsychotic treatment. Am. J. Psych.158, 176–184 (2001).
   PubMed Web of Science ®Google Scholar
• Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J. Clin. Psychopharmacol.21, 479–483 (2001).
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psych. 161(6), 985–995 (2004).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Siu CO, Romano S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl.)172(3), 324–332 (2004).
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J et al. Neurcognitive effects of clozapine, olanzapine, risperidone, haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psych.159(6), 1018–1028, (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Greenberg RD, Griffin SJ et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psych.162, 43–48 (1993).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Rabinowitz J, Eerdekens M et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am. J. Psych.162(10), 1888–1895 (2005).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Napolitano J, Mao L, Gharabawi G. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int. J. Ger. Psych.18, 820–829 (2003).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. J. Neuropsychiatry Clin. Neurosci.18(1), 54–63 (2006).
   PubMed Web of Science ®Google Scholar
• Malhotra AK, Burdick KE, Razi K, Bates JA, Sanders M, Kane JM. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity? Schizophr. Res.87(1–3), 181–184 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman JI, Adler DN, Temporini HD et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacol.25(3), 402–409 (2001).
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Summerfelt A, Tek C, Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res.59(1), 29–33 (2003).
   PubMed Web of Science ®Google Scholar
• Risch SC, McGurk S, Homer MD et al. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase7(2), 105–110 (2001).
   PubMed Web of Science ®Google Scholar
• Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin. Neuropharmacol.28(4), 179–184 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman JI, Adler DN, Howanitz E et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psych.51(5), 349–357 (2002).
   PubMed Web of Science ®Google Scholar
• Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A. A double-blind placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol.7(2), 117–123 (2004).
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Herz L, Deckersbach T et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology181(2), 358–363 (2005).
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psych.57(6), 577–585 (2005).
   PubMed Web of Science ®Google Scholar
• Good KP, Rabinowitz J, Whitehorn D et al. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr. Res.68(1), 11–19 (2004).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Serper MR, White L et al. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr. Psych.42, 306–313 (2001).
   PubMed Web of Science ®Google Scholar
• Bowie CR, Fallon C, Harvey PD. Assessment of schizophrenia patients in nursing homes: relationships between clinical staff ratings and research ratings. Psychiatr. Serv.57, 838–843 (2006).
   PubMed Web of Science ®Google Scholar
• Goff DC, Tsai G, Levitt J et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psych.56(1), 211–217 (1999).
   Google Scholar
• Goff DC, Herz L, Posever T et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology179(1), 144–150 (2005).
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur. Neuropsychopharmacol.13(2), 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Friedman JI, Ocampo R, Elbaz Z et al. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J. Clin. Psychopharmacol.25(3), 237–242 (2005).
   PubMed Web of Science ®Google Scholar
• Levin ED, Rezvani AH. Nicotinic-antipsychotic drug interactions and cognitive function. EXS98, 185–205 (2006).
   PubMedGoogle Scholar
• Smith RC, Warner-Cohen J, Matute M et al. Effects of nicotine spray on cognitive function in schizophrenia. Neuropsychopharmacol.31, 637–643 (2006).
   PubMed Web of Science ®Google Scholar
• Olincy A, Harris JG, Johnson LL et al. Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia. Arch. Gen. Psychiatry63, 630–638 (2006).
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hinze-Selch D, Stawicki S et al. Improvement of cognitive functions in chornic schizophrenic patients by recombinant human erythropoietin. Mol. Psychiatry12(2), 206–220 (2007).
   PubMed Web of Science ®Google Scholar
• Fizdon JM, Bryson GJ, Wexler BE et al. Durability of cognitive remediation training in schizophrenia: performance on two memory tasks at 6-month and 12-month follow-up. Psychiatry Res.125(1), 1–7 (2004).
   PubMed Web of Science ®Google Scholar
• Hogarty GE, Flesher S, Ulrich R et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch. Gen. Psych.61(9), 866–876 (2004).
   PubMed Web of Science ®Google Scholar
• McGurk SR, Mueser KT, Pascaris A. Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr. Bull.31(4), 898–909 (2005).
   PubMed Web of Science ®Google Scholar
• Wexler BE, Bell MD. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr. Bull.31(4), 931–941 (2005).
   PubMed Web of Science ®Google Scholar
• Velligan DI, Prihoda TJ, Ritch JL et al. A randomized single-blind study of compensatory strategies in schizophrenia outpatients. Schizophr. Bull.28(2), 283–292 (2002).
   Google Scholar
• Kawai N, Yamakawa Y, Baba A et al. High-dose of multiple antiopsychotics and cognitive function in schizophrenia: the effect of dose reduction. Prog. Neuropsychopharmacol. Biol. Psychiatry30, 1009–1014 (2006).
   PubMed Web of Science ®Google Scholar
• Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr. Res.72, 5–9 (2004).
   PubMed Web of Science ®Google Scholar
• McClure MM, Bowie CR, Patterson TL et al. Correlations of functional capacity and neuropsychological performance in older schizophrenia: evidence for specificity of relationships? Schizophr. Res.89(1–3), 330–338 (2007).
   PubMed Web of Science ®Google Scholar
• Kumari V, Aasen I, Ffytche D et al. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage29(2), 545–556 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr. Res. 85(1–3), 73–83 (2006).
   PubMed Web of Science ®Google Scholar
• Bowie CR, Reichenberg A, Patterson TL et al. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psych.163, 418–425 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Leslie D, Keefe R et al. CATIE Study Investigators Group. Barriers to employment for people with schizophrenia. Am. J. Psych. 163(3), 411–417 (2006).
   PubMed Web of Science ®Google Scholar
• Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am. J. Psych.163, 1918–1925 (2006).
   PubMed Web of Science ®Google Scholar